Is it necessary to strictly diagnose fibromyalgia syndrome in patients with chronic widespread pain?

On, Arzu Yağız; Aykanat, Dilek; Atamaz, Funda; Eyigör, Can; Kocanogullari, Hayriye; Öksel, Fahrettin

doi:10.1007/s10067-015-2975-1

Cited by 8 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In non-nociceptive pain, my treatments of patients with FM and without FM are generally identical. The diagnostic criteria of FM are useful for diagnosis; however, they are not useful for treatment [56]. To put it briefly, I believe that the significance of the criteria is to identify uniform patients with FM in medical journals and/or medical meetings.…”

Section: Discussionmentioning

confidence: 99%

Comparison of treatment outcomes between fibromyalgia and the incomplete form of fibromyalgia with the same treatment

Toda¹

2018

Pharm Drug Dev Ther

View full text Add to dashboard Cite

Objective: The treatment outcomes of fibromyalgia (FM) and the incomplete form of FM (I-FM) (chronic widespread pain and chronic regional pain) in one medical institution were compared using the same FM treatment (mainly medication).Methods: Patients with FM consisted of 31 persons (25 women and 6 men) and the average age was 37.4 ± 15.9 years old (range: 17 to 84 years old). Patients with I-FM consisted of 49 persons (37 women and 12 men) and the average age was 50.3 ± 16.8 years old (range: 16 to 86 years old). Pain was estimated in this study as follows: "If pain at the first visit is 100, what percentage is the current pain?" All patients with FM and I-FM who received medication for more than 3 months including dropout patients were included in this study. The mean treatment duration of patients with FM was 13.3 ± 9.1 months (range: 3 to 32 months) and that of patients with I-FM was 12.1 ± 7.4 months (range: 3 to 34 months).Results: Cure was achieved in 0 (0%) and 3 (6.1%) patients, and pain was reduced to 30% or less in 7 (22.6%) and 21 (42.9%), 31-50% was 3 (9.7%) and 8 (16.3%), 51-70% was 9 (29.0%) and 5 (10.2%), 71-90% was 6 (19.4%) and 4 (8.2%), and 91% or more was 6 (19.4%) and 8 (16.3%), of FM and I-FM patients, respectively. Discussion: Because the treatment outcome of I-FM was better than that of FM, it is desirable to provide treatment before FM actually develops.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of treatment outcomes between fibromyalgia and the incomplete form of fibromyalgia with the same treatment

Toda¹

2018

Pharm Drug Dev Ther

View full text Add to dashboard Cite

show abstract

“…In their recent study, Arzu Yagiz On and colleagues at Ege-University have also raised this issue [1] . They reported a survey of 284 patients with CWP, who had admitted to Physical Medicine and Rehabilitation, Algology and Rheumatology clinics of a university hospital.…”

Section: Research Highlightmentioning

confidence: 98%

“…My suggestion does not mean to ignore currently available diagnostic criteria for FMS. Previous studies, including ours demonstrated that the patients with CWP who had satisfied the TP criterion of the ACR 1990 seemed to have greater disease burden with more severe pain, more comorbidities and pain related medications, and worse overall health comparing to those who had not [1,[146][147][148][149][150][151] . In their recent study, Jimenez et al found that patients fulfilling the modified 2010 only had worse symptom profile than those fulfilling the 1990 criteria only [152] .…”

Section: Research Highlightmentioning

confidence: 99%

Fibromyalgia or Chronic Widespread Pain: Does It Matter?

2016

Itch Pain

View full text Add to dashboard Cite

The question whether Fibromyalgia syndrome (FMS) is a distinct clinical entity in the context of chronic widespread pain (CWP) have remained challenging after decades of research and several diagnostic criteria that have attempted to clarify FMS. A recent study has raised more challenges on the issue, proposing that diagnosis of FMS in patients representing with CWP is not informative or helpful for clinical practice and such a differentiation will provide little or no significance regarding the choice of effective and safe therapies. This proposal will be further discussed here by reviewing the recent advances in the field of pain medicine. These advances have collectively provided compelling evidence that all individuals with chronic pain, even those classically categorized as originating from peripheral/nociceptive origins have common central contributions to their pain and associated comorbidities. The recent understanding of the pain mechanisms has also provided important implications on classification and management of pain. Centrally acting agents have been recommended as first-line treatment options for FMS and potential use of these agents has been expanded to other chronic pain disorders. After having reviewed the recent advances in the pain field, distinction between CWP and FMS still seems not to be useful in clinical practice, as effective treatment in an individual patient might be much guided by dominant underlying mechanisms rather than specific diagnosis the patient is suffering. The conditions representing with CWP in the absence of definitive objective confirmation may then be classified under one heading such as "CWP", "chronic pain syndrome" or "central pain", when considering their similar pattern of clinical presentation, commonality of central sensitization to their pathophysiology and their similar response to centrally acting analgesics. Future research should be directed toward classification of CWP based on the validated measurements of different aspects of pain. Such a classification may help clinicians identify the patients who will preferentially respond to peripheral or centrally acting analgesics and may therefore assist in advancing a more individualized and pain mechanism focused treatment in the clinical setting.

show abstract

“…Bu gelişmeler ışığında artık, FMS'nin artık, santral sensitizasyona bağlı kronik yaygın ağrı spektrumunun en uç örneği kabul edilmesi gerektiği görüşü yaygınlaşmaktadır (17)(18)(19).…”

Section: Etiyoloji Ve Patogenezunclassified

The role of fibromyalgia in rheumatic diseases

2019

Ege Tıp Dergisi

View full text Add to dashboard Cite

Romatolojik hastalıklarda fibromiyaljinin payı The role of fibromyalgia in rheumatic diseases Arzu On Ege Üniversitesi Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı Öz Fibromiyalji sendromu (FMS), kronik yaygın kas-iskelet ağrısı, yaygın hassas noktalar, multipl somatik ve bilişsel problemlerle karakterize, spesifik laboratuvar ve görüntüleme bulgusu olmayan klinik bir sendromdur. Kronik romatolojik hastalıklarda FMS prevalansının genel popülasyona göre daha yüksek olduğu gösterilmiştir. Komorbid FMS hastalık aktivite skorlarının yükselmesine, dolayısıyla romatolojik hastalığın şiddetinin yanlış değerlendirilmesine ve gereksiz tedavilerin verilmesine neden olabilir. Bu nedenle eşlik eden FMS'nun tanınması, romatolojik hastalığın optimal tedavisi için önem taşır. Komorbid FMS olan olgularda hastalık aktivite göstergeleri dikkatle yorumlanmalı, objektif klinik ölçütler göz önünde bulundurulmalıdır. Bu derlemede, değişik romatolojik hastalıklarda komorbid FMS prevalansı, patofizyolojisi ve altta yatan inflamatuvar hastalık üzerindeki etkileri gözden geçirilecektir.

show abstract

Is it necessary to strictly diagnose fibromyalgia syndrome in patients with chronic widespread pain?

Cited by 8 publications

References 30 publications

Comparison of treatment outcomes between fibromyalgia and the incomplete form of fibromyalgia with the same treatment

Comparison of treatment outcomes between fibromyalgia and the incomplete form of fibromyalgia with the same treatment

Fibromyalgia or Chronic Widespread Pain: Does It Matter?

The role of fibromyalgia in rheumatic diseases

Contact Info

Product

Resources

About